Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative disorders, has shared its financial results and updated it for the first quarter of 2024.
The company’s lead drug, ALPHA-1062, is undergoing review by the FDA for mild-to-moderate Alzheimer’s disease. Alpha Cognition is actively planning for its commercialization and manufacturing, anticipating a PDUFA date of July 2024. If approved, ALPHA-1062 is expected to offer a unique treatment option for Alzheimer’s patients.
ALPHA-1062 is a patented acetylcholinesterase inhibitor designed with minimal gastrointestinal side effects. Its active metabolite interacts with neuronal nicotinic receptors, particularly the alpha-7 subtype, which has positive cognitive effects. The drug is also being developed in combination with memantine for moderate to severe Alzheimer’s disease, a sublingual formulation for dysphagia patients, and an intranasal formulation for cognitive impairment related to mTBI (concussion).
Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases with limited options. The company believes ALPHA-1062 has the potential to make a meaningful difference in the lives of patients with Alzheimer’s dementia. Forward-looking statements made in this release involve risks and uncertainties that could impact the company’s results and the development of its products.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
